Drug Development

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Development of Gamma-Delta T-Cell Therapies

Activation and expansion are essential for success in both autologous and allogeneic therapies.

QbD for Small-Molecule Continuous Process Development

Continuous manufacturing and a quality-by-design development approach are a natural fit.

Tome brings $213 Million to the Programmable Genome Editing Party

December 28, 2023

Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.

Daiichi Sankyo Partners with Depixus to Accelerate RNA-Targeted Drug Discovery

December 20, 2023

Under a collaboration, Daiichi Sankyo and Depixus will use Depixus’ MAGNA technology to accelerate drug discovery efforts of RNA-targeted therapeutics.

Bristol Myers Squibb and SystImmune Enter Global ADC Collaboration Worth Potentially up to $8.4 Billion

December 19, 2023

Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.

Compounding Overview: Primary Considerations in the Workplace

December 18, 2023

Technical, regulatory, and personnel considerations characterize pharmaceutical compounding.

FDA Announces Advisory Committee for Genetic Metabolic Disease Treatments

December 13, 2023

The new advisory committee will provide the agency with technical and scientific advice and recommendations on potential treatments for genetic metabolic diseases.

Absci and AstraZeneca Collaborate on AI-Driven Oncology Candidate

December 05, 2023

AstraZeneca will utilize Absci’s AI antibody drug creation platform to create an AI-designed antibody.

Selecting Excipients for Enhancing Solubility of Hot-Melt Extrusion Formulations

December 03, 2023

Matching excipients to API properties is essential.

Risks and Rewards of Investing in RNA-based Genetic Medicine Manufacturing

December 03, 2023

Collaboration is a key component to achieving long-term success with genetic medicines.

New Medicines, Markets, and Manufacture: CRISPR for Sickle Cell Disease and β-thalassemia

November 30, 2023

Exagamglogene autotemcel seen as synechdoche.

Genentech and NVIDIA Form AI Research Collaboration for Drug Discovery and Development

November 29, 2023

Under this multi-year collaboration, Genentech and NVIDIA will use AI to optimize and accelerate each company’s platforms to discover and develop innovative therapeutics.